Deargen
AI-powered drug design biotech company advancing treatments for rare and intractable diseases through genome data analysis and molecule optimization.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
$17.0m | Series B | ||
| Total Funding | 000k | ||
Related Content
Deargen Inc. is a biotechnology company that leverages advanced Artificial Intelligence (AI) to revolutionize the development of new drugs, particularly for rare and intractable diseases. The company operates in the pharmaceutical and healthcare markets, focusing on integrating AI with drug discovery processes to enhance efficiency and precision. Deargen's AI platform, Dr.UG, utilizes deep learning technology to analyze genome data, predict biomarkers, and select and optimize molecules for drug development. This approach allows Deargen to identify new disease targets and design small molecules for precision medicine.
Deargen serves pharmaceutical companies, research institutions, and healthcare providers who are looking for innovative solutions to accelerate drug discovery and development. The company's business model is based on partnerships and collaborations, both corporate and scientific, to co-develop new treatments and bring them to market. Revenue is generated through these partnerships, licensing agreements, and potentially through the commercialization of successful drug candidates.
Keywords: AI-powered, drug design, biotechnology, rare diseases, genome analysis, biomarker prediction, molecule optimization, precision medicine, pharmaceutical partnerships, deep learning.